A Multicentre Double-blind, Placebo-controlled, Randomised, Parallel-group Study to Evaluate the Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer's Disease.
Phase of Trial: Phase II
Latest Information Update: 15 Apr 2016
At a glance
- Drugs Lornoxicam (Primary)
- Indications Alzheimer's disease
- Focus Biomarker; Therapeutic Use
- 01 Jun 2012 Additional trial locations added as reported by European Clinical Trials Database.
- 01 Jun 2012 Company added in association field as reported by European Clinical Trials Database.
- 31 Mar 2012 This trial has been recruiting in Slovakia, completed in Germany and; discontinued in Czech Republic and Austria as reported by European Clinical Trials Database record.